Daniela Dinulescu
Director - Tumor Immunobiology, Clinical ICC Discovery Group, Oncology Research & Development AstraZeneca
Seminars
Wednesday 29th July 2026
Panel Discussion: Overcoming Challenges with Access to Tissues & Patient Samples to Build Better Patient-Derived Tumor Models & Enhance Translational Success
3:40 pm
- Highlighting why high quality, well annotated patient derived samples are essential for building tumor models that truly reflect human disease and improve translational confidence
- Delving into how collaboration between drug developers, clinicians, and model providers accelerates access to the right tissues at the right time and strengthens preclinical decision making
- Discussing practical strategies to overcome ethical, logistical, and operational barriers i tissue procurement to enhance reproducibility and boost trust in model‑derived data
Thursday 30th July 2026
Building & Validating the Predictive Power of a Patient-Derived Ex Vivo Platform to Guide Bispecific Development & Clinical Strategy
3:30 pm
- Showcasing a patient derived ex vivo platform to test drugs and combinations directly in primary tumor material, enabling precise assessment of therapeutic index, responder likelihood and patient selection strategies before entering the clinic
- Spotlighting a PD‑1/TIGIT bispecific case study across lung and head & neck cancers, demonstrating how ex vivo response patterns aligned with clinical outcomes to validate predictive capability and inform indication prioritisation
- Discussing how AI and foundation models are trained on ex vivo datasets to build predictive classifiers that guide clinical trial design, linking molecular signatures, functional drug responses and patient specific biology to real translational decision making
